LeonaBio Inc (LONA)

LeonaBio Inc. witnessed a significant single purchase of 3,149,470 shares by David J. Portman on October 26, 2026, valued at approximately $9.9 billion. This follows a period of consistent divestment by various executives earlier in the year. The stock has declined 48.9% over the past ninety days, preceding the most recent November earnings report.
Ticker: LONA Exchange: NAS


Loading...
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for LeonaBio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Portman David J. Large shareholder
Transaction date
Purchase
Price
10.96
Quantity 32,236 +46.7%
Value US$448,026
2.1
Litton Mark James PRESIDENT and CEO Executive Director
Transaction date
Sale
Price
458.68
Quantity 94,883 +18.0%
Value US$1,554,291
1.8
Renninger Robert CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
408.72
Quantity 93,329 -16.4%
Value US$658,119
2.2
Worthington Mark GENERAL COUNSEL and CCO Officer
Transaction date
Sale
Price
5.37
Quantity 1,328 -6.7%
Value US$7,131
2.0
CHURCH KEVIN CHIEF SCIENTIFIC OFFICER Officer
Transaction date
Sale
Price
5.37
Quantity 1,359 -5.1%
Value US$7,298
3.1
San Martin Javier CHIEF MEDICAL OFFICER Officer
Transaction date
Sale
Price
5.37
Quantity 1,720 -9.8%
Value US$9,236
2.1
Mark James Litton Officer; Director Executive Director
Transaction date
Proposed sale
Price
5.36
Quantity 5,156
Value US$27,662
2.1
Litton Mark James President and CEO Executive Director
Transaction date
Sale
Price
6.88
Quantity 2,586 -6.0%
Value US$17,792
1.8
Renninger Robert Chief Financial Officer Officer
Transaction date
Sale
Price
6.88
Quantity 297 -2.3%
Value US$2,043
3.1
San Martin Javier CHIEF MEDICAL OFFICER Officer
Transaction date
Sale
Price
6.88
Quantity 1,644 -13.9%
Value US$11,311
2.0
CHURCH KEVIN CHIEF SCIENTIFIC OFFICER Officer
Transaction date
Sale
Price
6.88
Quantity 876 -4.1%
Value US$6,027
2.2
Worthington Mark General Counsel and CCO Officer
Transaction date
Sale
Price
6.88
Quantity 876 -5.9%
Value US$6,027
1.8
Renninger Robert SVP, Finance and Accounting Officer
Transaction date
Sale
Price
0.29
Quantity 2,897 -2.6%
Value US$850
2.2
Worthington Mark General Counsel and CCO Officer
Transaction date
Sale
Price
0.29
Quantity 8,526 -7.1%
Value US$2,502
2.0
CHURCH KEVIN CHIEF SCIENTIFIC OFFICER Officer
Transaction date
Sale
Price
0.29
Quantity 8,526 -4.8%
Value US$2,502
2.1
Litton Mark James President and CEO Executive Director
Transaction date
Sale
Price
0.29
Quantity 25,123 -7.2%
Value US$7,374
3.1
San Martin Javier CHIEF MEDICAL OFFICER Officer
Transaction date
Sale
Price
0.29
Quantity 10,842 -13.1%
Value US$3,182
2.1
Mark James Litton Officer; Director Executive Director
Transaction date
Proposed sale
Price
0.29
Quantity 25,123
Value US$7,374
3.1
Javier San Martin Officer Officer
Transaction date
Proposed sale
Price
0.29
Quantity 10,842
Value US$3,182
2.0
Kevin Church Officer Officer
Transaction date
Proposed sale
Price
0.29
Quantity 8,526
Value US$2,502
2.2
Mark Worthington Officer Officer
Transaction date
Proposed sale
Price
0.29
Quantity 8,526
Value US$2,502
3.1
San Martin Javier CHIEF MEDICAL OFFICER Officer
Transaction date
Sale
Price
0.56
Quantity 10,826 -23.2%
Value US$6,083
2.2
Worthington Mark General Counsel and CCO Officer
Transaction date
Sale
Price
0.56
Quantity 8,510 -9.2%
Value US$4,782
1.8
Renninger Robert VP of Finance Officer
Transaction date
Sale
Price
0.56
Quantity 2,881 -3.1%
Value US$1,619
2.1
Litton Mark James President and CEO Executive Director
Transaction date
Sale
Price
0.56
Quantity 25,107 -9.4%
Value US$14,108
2.0
CHURCH KEVIN CHIEF SCIENTIFIC OFFICER Officer
Transaction date
Sale
Price
0.56
Quantity 8,510 -6.1%
Value US$4,782
3.1
Javier San Martin Officer Officer
Transaction date
Proposed sale
Price
0.56
Quantity 10,826
Value US$6,083
2.1
Mark James Litton Officer; Director Executive Director
Transaction date
Proposed sale
Price
0.56
Quantity 25,107
Value US$14,108
2.2
Mark Worthington Officer Officer
Transaction date
Proposed sale
Price
0.56
Quantity 8,510
Value US$4,782
2.0
Kevin Church Officer Officer
Transaction date
Proposed sale
Price
0.56
Quantity 8,510
Value US$4,782
2.1
Mark James Litton Officer; Director Executive Director
Transaction date
Proposed sale
Price
0.00
Quantity 5,032
Value US$1
2.0
Lenington Rachel COO and CDO Officer
Transaction date
Sale
Price
0.57
Quantity 2,525 -10.8%
Value US$1,429
2.2
Worthington Mark GENERAL COUNSEL Officer
Transaction date
Sale
Price
0.57
Quantity 2,525 -4.6%
Value US$1,429
2.0
CHURCH KEVIN CHIEF SCIENTIFIC OFFICER Officer
Transaction date
Sale
Price
0.57
Quantity 2,525 -2.7%
Value US$1,429
1.8
Gengos Andrew CFO and Chief Business Officer Officer
Transaction date
Sale
Price
0.57
Quantity 1,272 -1.3%
Value US$720
2.1
Litton Mark James President and CEO Executive Director
Transaction date
Sale
Price
0.57
Quantity 5,032 -3.1%
Value US$2,848
2.0
Romano Kelly A Non-Executive Director
Transaction date
Purchase
Price
2.42
Quantity 27,400 +51.4%
Value US$66,179
2.0
Romano Kelly A Non-Executive Director
Transaction date
Purchase
Price
2.26
Quantity 15,000 +39.1%
Value US$33,872
2.0
Lenington Rachel Chief Operating Officer Officer
Transaction date
Sale
Price
2.91
Quantity 2,412 -15.3%
Value US$7,019
2.2
Worthington Mark General Counsel Officer
Transaction date
Sale
Price
2.91
Quantity 2,412 -6.5%
Value US$7,019
2.1
Litton Mark James Chief Executive Officer Executive Director
Transaction date
Sale
Price
2.91
Quantity 4,820 -3.2%
Value US$14,026
2.7
PERCEPTIVE ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.38
Quantity 163,954 +3.1%
Value US$390,211
2.7
PERCEPTIVE ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.44
Quantity 409,598 +8.5%
Value US$999,419
2.7
PERCEPTIVE ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.28
Quantity 32,134 +0.7%
Value US$73,266
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
3.44
Quantity 11,719 +17.2%
Value US$40,308
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
3.40
Quantity 2,859 +4.4%
Value US$9,721
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
3.36
Quantity 422 +0.6%
Value US$1,417
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
3.02
Quantity 10,000 +18.2%
Value US$30,154
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
3.00
Quantity 10,000 +22.2%
Value US$29,999
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
3.00
Quantity 10,000 +28.6%
Value US$29,997
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
3.00
Quantity 15,000 +75.0%
Value US$45,000
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
2.95
Quantity 3,418 +20.6%
Value US$10,066
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
2.86
Quantity 6,582 +65.7%
Value US$18,823
1.8
Gengos Andrew See Below Officer
Transaction date
Purchase
Price
2.75
Quantity 10,012 New position
Value US$27,533
3.1
JOHNSON JAMES A Non-Executive Director
Transaction date
Purchase
Price
2.40
Quantity 5,000 New position
Value US$12,000
1.8
Gengos Andrew See Below Officer
Transaction date
Sale
Price
2.91
Quantity 1,208 -1.4%
Value US$3,515
2.0
CHURCH KEVIN Chief Scientific Officer Officer
Transaction date
Sale
Price
2.91
Quantity 2,412 -2.9%
Value US$7,019
2.1
MILESON GLENNA Chief Financial Officer Officer
Transaction date
Purchase
Price
2.85
Quantity 50,000 +45.5%
Value US$142,250
2.0
Romano Kelly A Non-Executive Director
Transaction date
Purchase
Price
3.29
Quantity 30,000 +360.8%
Value US$98,700
1.4
MOEBIUS HANS Chief Medical Officer Officer
Transaction date
Purchase
Price
3.29
Quantity 5,000 +8.2%
Value US$16,442
2.7
PERCEPTIVE ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.99
Quantity 1,101,362 +29.8%
Value US$3,293,072
2.7
PERCEPTIVE ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.99
Quantity 270,000 +7.9%
Value US$807,300
2.2
Worthington Mark General Counsel Officer
Transaction date
Sale
Price
2.69
Quantity 2,614 -12.0%
Value US$7,032
2.0
Lenington Rachel Chief Operating Officer Officer
Transaction date
Sale
Price
2.69
Quantity 4,193 -41.9%
Value US$11,279
2.1
Litton Mark James Chief Executive Officer Executive Director
Transaction date
Sale
Price
2.69
Quantity 7,960 -5.8%
Value US$21,412
2.1
MILESON GLENNA Chief Financial Officer Officer
Transaction date
Sale
Price
2.69
Quantity 2,614 -2.3%
Value US$7,032
2.0
CHURCH KEVIN Executive VP, Research Officer
Transaction date
Sale
Price
2.69
Quantity 2,614 -4.3%
Value US$7,032
2.0
Romano Kelly A Non-Executive Director
Transaction date
Purchase
Price
13.11
Quantity 8,000 +2539.7%
Value US$104,880
2.7
PERCEPTIVE ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
22.50
Quantity 311,111 +10.0%
Value US$6,999,998
3.9
EDELMAN JOSEPH Non-Executive Director Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 1,058,824 +51.5%
Value US$18,000,008
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 1,058,824 +51.5%
Value US$18,000,008
2.7
RTW INVESTMENTS, LP Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 750,000 +39.1%
Value US$12,750,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-10-28 2026-10-26 B Purchase Large shareholder
32,236 +46.7%
10.96
US$448,026
32,236 +46.7% 10.96 US$448,026
2026-03-05 2026-03-04 S Sale

PRESIDENT and CEO

Executive Director
94,883 +18.0%
458.68
US$1,554,291
94,883 +18.0% 458.68 US$1,554,291
2026-03-05 2026-03-04 S Sale

CHIEF FINANCIAL OFFICER

Officer
93,329 -16.4%
408.72
US$658,119
93,329 -16.4% 408.72 US$658,119
2026-03-05 2026-03-04 S Sale

GENERAL COUNSEL and CCO

Officer
1,328 -6.7%
5.37
US$7,131
1,328 -6.7% 5.37 US$7,131
2026-03-05 2026-03-04 S Sale

CHIEF SCIENTIFIC OFFICER

Officer
1,359 -5.1%
5.37
US$7,298
1,359 -5.1% 5.37 US$7,298
2026-03-05 2026-03-04 S Sale

CHIEF MEDICAL OFFICER

Officer
1,720 -9.8%
5.37
US$9,236
1,720 -9.8% 5.37 US$9,236
2026-03-04 2026-03-04 PrS Proposed sale

Officer; Director

Executive Director
5,156
5.36
US$27,662
5,156 5.36 US$27,662
2026-01-05 2026-01-02 S Sale

President and CEO

Executive Director
2,586 -6.0%
6.88
US$17,792
2,586 -6.0% 6.88 US$17,792
2026-01-05 2026-01-02 S Sale

Chief Financial Officer

Officer
297 -2.3%
6.88
US$2,043
297 -2.3% 6.88 US$2,043
2026-01-05 2026-01-02 S Sale

CHIEF MEDICAL OFFICER

Officer
1,644 -13.9%
6.88
US$11,311
1,644 -13.9% 6.88 US$11,311
2026-01-05 2026-01-02 S Sale

CHIEF SCIENTIFIC OFFICER

Officer
876 -4.1%
6.88
US$6,027
876 -4.1% 6.88 US$6,027
2026-01-05 2026-01-02 S Sale

General Counsel and CCO

Officer
876 -5.9%
6.88
US$6,027
876 -5.9% 6.88 US$6,027
2025-07-02 2025-07-01 S Sale

SVP, Finance and Accounting

Officer
2,897 -2.6%
0.29
US$850
2,897 -2.6% 0.29 US$850
2025-07-02 2025-07-01 S Sale

General Counsel and CCO

Officer
8,526 -7.1%
0.29
US$2,502
8,526 -7.1% 0.29 US$2,502
2025-07-02 2025-07-01 S Sale

CHIEF SCIENTIFIC OFFICER

Officer
8,526 -4.8%
0.29
US$2,502
8,526 -4.8% 0.29 US$2,502
2025-07-02 2025-07-01 S Sale

President and CEO

Executive Director
25,123 -7.2%
0.29
US$7,374
25,123 -7.2% 0.29 US$7,374
2025-07-02 2025-07-01 S Sale

CHIEF MEDICAL OFFICER

Officer
10,842 -13.1%
0.29
US$3,182
10,842 -13.1% 0.29 US$3,182
2025-07-01 2025-07-01 PrS Proposed sale

Officer; Director

Executive Director
25,123
0.29
US$7,374
25,123 0.29 US$7,374
2025-07-01 2025-07-01 PrS Proposed sale

Officer

Officer
10,842
0.29
US$3,182
10,842 0.29 US$3,182
2025-07-01 2025-07-01 PrS Proposed sale

Officer

Officer
8,526
0.29
US$2,502
8,526 0.29 US$2,502
2025-07-01 2025-07-01 PrS Proposed sale

Officer

Officer
8,526
0.29
US$2,502
8,526 0.29 US$2,502
2025-01-03 2025-01-02 S Sale

CHIEF MEDICAL OFFICER

Officer
10,826 -23.2%
0.56
US$6,083
10,826 -23.2% 0.56 US$6,083
2025-01-03 2025-01-02 S Sale

General Counsel and CCO

Officer
8,510 -9.2%
0.56
US$4,782
8,510 -9.2% 0.56 US$4,782
2025-01-03 2025-01-02 S Sale

VP of Finance

Officer
2,881 -3.1%
0.56
US$1,619
2,881 -3.1% 0.56 US$1,619
2025-01-03 2025-01-02 S Sale

President and CEO

Executive Director
25,107 -9.4%
0.56
US$14,108
25,107 -9.4% 0.56 US$14,108
2025-01-03 2025-01-02 S Sale

CHIEF SCIENTIFIC OFFICER

Officer
8,510 -6.1%
0.56
US$4,782
8,510 -6.1% 0.56 US$4,782
2025-01-02 2025-01-02 PrS Proposed sale

Officer

Officer
10,826
0.56
US$6,083
10,826 0.56 US$6,083
2025-01-02 2025-01-02 PrS Proposed sale

Officer; Director

Executive Director
25,107
0.56
US$14,108
25,107 0.56 US$14,108
2025-01-02 2025-01-02 PrS Proposed sale

Officer

Officer
8,510
0.56
US$4,782
8,510 0.56 US$4,782
2025-01-02 2025-01-02 PrS Proposed sale

Officer

Officer
8,510
0.56
US$4,782
8,510 0.56 US$4,782
2024-09-05 2024-09-05 PrS Proposed sale

Officer; Director

Executive Director
5,032
0.00
US$1
5,032 0.00 US$1
2024-09-05 2024-09-05 S Sale

COO and CDO

Officer
2,525 -10.8%
0.57
US$1,429
2,525 -10.8% 0.57 US$1,429
2024-09-05 2024-09-05 S Sale

GENERAL COUNSEL

Officer
2,525 -4.6%
0.57
US$1,429
2,525 -4.6% 0.57 US$1,429
2024-09-05 2024-09-05 S Sale

CHIEF SCIENTIFIC OFFICER

Officer
2,525 -2.7%
0.57
US$1,429
2,525 -2.7% 0.57 US$1,429
2024-09-05 2024-09-05 S Sale

CFO and Chief Business Officer

Officer
1,272 -1.3%
0.57
US$720
1,272 -1.3% 0.57 US$720
2024-09-05 2024-09-05 S Sale

President and CEO

Executive Director
5,032 -3.1%
0.57
US$2,848
5,032 -3.1% 0.57 US$2,848
2024-06-25 2024-06-24 B Purchase Non-Executive Director
27,400 +51.4%
2.42
US$66,179
27,400 +51.4% 2.42 US$66,179
2024-06-25 2024-06-21 B Purchase Non-Executive Director
15,000 +39.1%
2.26
US$33,872
15,000 +39.1% 2.26 US$33,872
2024-01-08 2024-01-05 S Sale

Chief Operating Officer

Officer
2,412 -15.3%
2.91
US$7,019
2,412 -15.3% 2.91 US$7,019
2024-01-08 2024-01-05 S Sale

General Counsel

Officer
2,412 -6.5%
2.91
US$7,019
2,412 -6.5% 2.91 US$7,019
2024-01-08 2024-01-05 S Sale

Chief Executive Officer

Executive Director
4,820 -3.2%
2.91
US$14,026
4,820 -3.2% 2.91 US$14,026
2023-12-29 2023-12-29 B Purchase Non-Executive Director Large shareholder
163,954 +3.1%
2.38
US$390,211
163,954 +3.1% 2.38 US$390,211
2023-12-29 2023-12-28 B Purchase Non-Executive Director Large shareholder
409,598 +8.5%
2.44
US$999,419
409,598 +8.5% 2.44 US$999,419
2023-12-29 2023-12-27 B Purchase Non-Executive Director Large shareholder
32,134 +0.7%
2.28
US$73,266
32,134 +0.7% 2.28 US$73,266
2023-06-09 2023-06-07 B Purchase

See Below

Officer
11,719 +17.2%
3.44
US$40,308
11,719 +17.2% 3.44 US$40,308
2023-06-09 2023-06-07 B Purchase

See Below

Officer
2,859 +4.4%
3.40
US$9,721
2,859 +4.4% 3.40 US$9,721
2023-06-09 2023-06-07 B Purchase

See Below

Officer
422 +0.6%
3.36
US$1,417
422 +0.6% 3.36 US$1,417
2023-06-06 2023-06-05 B Purchase

See Below

Officer
10,000 +18.2%
3.02
US$30,154
10,000 +18.2% 3.02 US$30,154
2023-06-06 2023-06-05 B Purchase

See Below

Officer
10,000 +22.2%
3.00
US$29,999
10,000 +22.2% 3.00 US$29,999
2023-06-06 2023-06-05 B Purchase

See Below

Officer
10,000 +28.6%
3.00
US$29,997
10,000 +28.6% 3.00 US$29,997
2023-06-06 2023-06-05 B Purchase

See Below

Officer
15,000 +75.0%
3.00
US$45,000
15,000 +75.0% 3.00 US$45,000
2023-06-06 2023-06-02 B Purchase

See Below

Officer
3,418 +20.6%
2.95
US$10,066
3,418 +20.6% 2.95 US$10,066
2023-06-06 2023-06-02 B Purchase

See Below

Officer
6,582 +65.7%
2.86
US$18,823
6,582 +65.7% 2.86 US$18,823
2023-06-06 2023-06-02 B Purchase

See Below

Officer
10,012 New position
2.75
US$27,533
10,012 New position 2.75 US$27,533
2023-03-30 2023-03-29 B Purchase Non-Executive Director
5,000 New position
2.40
US$12,000
5,000 New position 2.40 US$12,000
2024-01-08 2023-01-05 S Sale

See Below

Officer
1,208 -1.4%
2.91
US$3,515
1,208 -1.4% 2.91 US$3,515
2024-01-08 2023-01-05 S Sale

Chief Scientific Officer

Officer
2,412 -2.9%
2.91
US$7,019
2,412 -2.9% 2.91 US$7,019
2022-12-30 2022-12-28 B Purchase

Chief Financial Officer

Officer
50,000 +45.5%
2.85
US$142,250
50,000 +45.5% 2.85 US$142,250
2022-12-06 2022-12-02 B Purchase Non-Executive Director
30,000 +360.8%
3.29
US$98,700
30,000 +360.8% 3.29 US$98,700
2022-11-17 2022-11-15 B Purchase

Chief Medical Officer

Officer
5,000 +8.2%
3.29
US$16,442
5,000 +8.2% 3.29 US$16,442
2022-07-01 2022-06-30 B Purchase Non-Executive Director Large shareholder
1,101,362 +29.8%
2.99
US$3,293,072
1,101,362 +29.8% 2.99 US$3,293,072
2022-07-01 2022-06-29 B Purchase Non-Executive Director Large shareholder
270,000 +7.9%
2.99
US$807,300
270,000 +7.9% 2.99 US$807,300
2022-06-24 2022-06-23 S Sale

General Counsel

Officer
2,614 -12.0%
2.69
US$7,032
2,614 -12.0% 2.69 US$7,032
2022-06-24 2022-06-23 S Sale

Chief Operating Officer

Officer
4,193 -41.9%
2.69
US$11,279
4,193 -41.9% 2.69 US$11,279
2022-06-24 2022-06-23 S Sale

Chief Executive Officer

Executive Director
7,960 -5.8%
2.69
US$21,412
7,960 -5.8% 2.69 US$21,412
2022-06-24 2022-06-23 S Sale

Chief Financial Officer

Officer
2,614 -2.3%
2.69
US$7,032
2,614 -2.3% 2.69 US$7,032
2022-06-24 2022-06-23 S Sale

Executive VP, Research

Officer
2,614 -4.3%
2.69
US$7,032
2,614 -4.3% 2.69 US$7,032
2022-04-01 2022-03-31 B Purchase Non-Executive Director
8,000 +2539.7%
13.11
US$104,880
8,000 +2539.7% 13.11 US$104,880
2021-01-27 2021-01-25 B Purchase Non-Executive Director Large shareholder
311,111 +10.0%
22.50
US$6,999,998
311,111 +10.0% 22.50 US$6,999,998
2020-09-22 2020-09-22 B Purchase Non-Executive Director Large shareholder
1,058,824 +51.5%
17.00
US$18,000,008
1,058,824 +51.5% 17.00 US$18,000,008
2020-09-22 2020-09-22 B Purchase Large shareholder
1,058,824 +51.5%
17.00
US$18,000,008
1,058,824 +51.5% 17.00 US$18,000,008
2020-09-22 2020-09-18 B Purchase Large shareholder
750,000 +39.1%
17.00
US$12,750,000
750,000 +39.1% 17.00 US$12,750,000